Table 1:
Characteristics of prevalent and incident Crohn’s disease (CD) and ulcerative colitis (UC) patients∆
| Variable | Prevalent treated CD and UC patients† (2014) | Incident treated CD and UC patients†(2010-2013) | ||||||
|---|---|---|---|---|---|---|---|---|
| Overall N = 29,879 | Anti-TNF N = 2,393 | Immunomodulator N = 8,387 | 5-ASA N = 14,484 | Matched comparators N = 146,934 | Overall N =12,687 | Matched comparators N =63,097 | ||
| Disease type, n (%) | ||||||||
| Crohn’s disease | 10,117 (33.9%) | 1,531 (64.0%) | 4,279 (51.0%) | 2,054 (14.2%) | 49,468 (33.7%) | 4, 028 (31.7%) | 20,055 (31.8%) | |
| Ulcerative colitis | 19,762 (66.1%) | 862 (36.0%) | 4,108 (49.0%) | 12,430 (85.8%) | 97,466 (66.3%) | 8,659 (68.3%) | 43,042 (68.2%) | |
| Female, n (%) | 14,532 (48.6%) | 1,016 (42.5%) | 3,847 (45.9%) | 7,150 (49.4%) | 71,498 (48.7%) | 6,482 (51.1%) | 32,254 (51.1%) | |
| Age (years) | ||||||||
| Mean (SD) | 50.1 (17.6) | 41.4 (15.2) | 46.3 (16.9) | 51.1 (17.4) | 50.1 (17.5) | 45.6 (19.1) | 45.6 (19.1) | |
| Median (25th-75th) | 49.7 (35.7-64.2) | 39.6 (28.2-52.1) | 45.6 (32.1-59.9) | 50.8 (37.1-65.0) | 49.7 (35.6-64.1) | 42.8 (28.5-61.6) | 42.8 (28.5-61.6) | |
| Range (min-max) | 18.0-100.6 | 18.0-83.9 | 18.0-95.8 | 18.0-100.6 | 18.0-99.7 | 18.0-100.6 | 18.0-100.9 | |
| 18-64 years, n (%) | 22,294 (74.6%) | 2,155 (90.1%) | 6,867 (81.9%) | 10,603 (73.2%) | 109,980 (74.8%) | 9,937 (78.3%) | 49,467 (78.4%) | |
| ≥ 65 years, n (%) | 7,585 (25.4%) | 238 (9.9%) | 1,520 (18.1%) | 3,881 (26.8%) | 36,954 (25.2%) | 2,750 (21.7%) | 13,630 (21.6%) | |
| Level of education, n (%) | ||||||||
| ≤9y | 5,343 (17.9%) | 309 (12.9%) | 1,306 (15.6%) | 2,545 (17.6%) | 25,815 (17.6%) | 2,313 (18.2%) | 11,520 (18.3%) | |
| 10-12y | 14,028 (46.9%) | 1,180 (49.3%) | 4,131 (49.3%) | 6,548 (45.2%) | 69,579 (47.4%) | 5,923 (46.7%) | 29,610 (46.9%) | |
| >12y | 10,361 (34.7%) | 887 (37.1%) | 2,911 (34.7%) | 5,327 (36.8%) | 51,171 (34.8%) | 4,318 (34.0%) | 21,552 (34.2%) | |
| Missing | 147 (0.5%) | 17 (0.7%) | 39 (0.5%) | 64 (0.4%) | 369 (0.3%) | 133 (1.0%) | 415 (0.7%) | |
| Comorbidities¶, n (%) | ||||||||
| Type 2 diabetes | 2,153 (7.2%) | 109 (4.6%) | 494 (5.9%) | 1,064 (7.3%) | 8,763 (6.0%) | 748 (5.9%) | 3,181 (5.0%) | |
| Cardiovascular disease | 3,158 (10.6%) | 150 (6.3%) | 667 (8.0%) | 1,455 (10.0%) | 11,059 (7.5%) | 1,298 (10.2%) | 4,173 (6.6%) | |
| Hypertension | 8,561 (28.7%) | 441 (18.4%) | 1,959 (23.4%) | 4,058 (28.0%) | 37,086 (25.2%) | 3,156 (24.9%) | 13,129 (20.8%) | |
| Chronic kidney disease | 876 (2.9%) | 56 (2.3%) | 201 (2.4%) | 247 (1.7%) | 1,882 (1.3%) | 310 (2.4%) | 706 (1.1%) | |
| Stroke | 411 (1.4%) | 20 (0.8%) | 92 (1.1%) | 199 (1.4%) | 1,616 (1.1%) | 186 (1.5%) | 669 (1.1%) | |
| Rheumatic diseases* | 1,618 (5.4%) | 301 (12.6%) | 575 (6.9%) | 389 (2.7%) | 3,280 (2.2%) | 549 (4.3%) | 1,229 (1.9%) | |
| Medication use, n (%) | ||||||||
| Anti-TNF agents with approved indication in CD or UC | 2,739 (9.2%) | 2,369 (99.0%) | 224 (2.7%) | 70 (0.5%) | 188 (0.1%) | 119 (0.9%) | 68 (0.1%) | |
| Other biologics | 43 (0.1%) | 37 (1.5%) | 2 (0.0%) | 0 | 29 (0.0%) | 6 (0.0%) | 1 (0.0%) | |
| Immunomodulators | 9,533 (31.9%) | 1,146 (47.9%) | 8,387 (100.0%) | 0 | 1,253 (0.9%) | 997 (7.9%) | 478 (0.8%) | |
| 5-aminosalicylic acid | 18,738 (62.7%) | 749 (31.3%) | 3,505 (41.8%) | 14,484 (100.0%) | 44 (0.0%) | 8,254 (65.1%) | 18 (0.0%) | |
| Corticosteroids* | 12,154 (40.7%) | 963 (40.2%) | 3,035 (36.2%) | 3,541 (24.4%) | 7,347 (5.0%) | 7,720 (60.8%) | 2,817 (4.5%) | |
| Other drugs | 27,408 (91.7%) | 2,229 (93.1%) | 7,699 (91.8%) | 12,950 (89.4%) | 103,328 (70.3%) | 12,276 (96.8%) | 43,632 (69.2%) | |
∆
Medication use was defined at the time of eligibility for prevalent cases and within the first month of diagnosis for incident cases.
†
Patients with >1 of anti-TNF, Immunomodulators, or 5-ASA treatment during the study period are included in more than one group, resulting in the n patients overall are not equal to the sum of drug groups.
¶
Represents any diagnostic codes within the last 5 years.
*
Includes rheumatoid arthritis, systemic lupus, psoriasis, and spondyloarthropathies. Includes budesonide use.